Up-Regulated Expression and Aberrant DNA Methylation of \( \text{LEP} \) and \( \text{SH3PXD2A} \) in Pre-Eclampsia

Yuqian Xiang\(^1\), Yan Cheng\(^2\), Xiaotian Li\(^2\), Qiaoli Li\(^1\), Jiawei Xu\(^1\), Junyu Zhang\(^1\), Yun Liu\(^1\), Qinghe Xing\(^1\), Lei Wang\(^1\), Lin He\(^1\)\(^{3,4}\), Xinzhi Zhao\(^1\)*

1 Children’s Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai, China, 2 Obstetrics & Gynecology Hospital of Fudan University, Shanghai, China, 3 Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China

**Abstract**

The primary mechanism underlying pre-eclampsia (PE) remains one of the most burning problems in the obstetrics and gynecology. In this study, we performed an expression profiling screen and detected 1312 genes that were differentially expressed \((p<0.05 \text{ and fold change } >1.5)\) in PE placentas, including \( \text{LEP} \) and \( \text{SH3PXD2A} \). After validating the microarray results, we conducted the quantitative methylation analysis of \( \text{LEP} \) and \( \text{SH3PXD2A} \) in preeclamptic \((n = 16)\) versus normal placentas \((n = 16)\). Our results showed that many CpG sites close to the transcriptional start site (TSS) of \( \text{LEP} \) gene were hypomethylated in placentas from pregnancies with PE compared with those of in controls, including the TSS position \((p = 0.001)\), the binding sites of Sp1 \((p = 1.57 \times 10^{-6})\), LP1 \((p = 0.023)\) and CEBPα \((p = 0.031)\). Luciferase reporter analysis confirmed the aberrant methylation of \( \text{LEP} \) promoter and CEBPα co-transfection had a role in the regulation of gene expression. Our results indicated the aberrant \( \text{LEP} \) promoter methylation was involved in the development of PE. We did not find a significant methylation differences between groups in the promoter region of \( \text{SH3PXD2A} \), however, a CGI region in the gene body \((\text{CGI34})\) presented a higher methylation in preeclamptic placentas \((p = 1.57 \times 10^{-6})\), which might promote the efficiency of gene transcription. We speculated that \( \text{SH3PXD2A} \) may take part in the pathogenesis of PE through its role in the regulation of trophoblast cell invasion in the period of placenta formation.

**Introduction**

Pre-eclampsia (PE; MIM 189800), a devastating pregnancy-associated disorder, is characterized by de-novo hypertension and proteinuria at or after 20 weeks’ gestation. The disease has a prevalence of 5–8% in nulliparous pregnancies and has been a leading cause of perinatal perinatal morbidity and mortality worldwide [1–3]. The World Health Organization (WHO) Nations has proposed the goals of PE treatment by reducing maternal mortality by 75% between 1990 and 2015 [4]. A great deal of researches have been conducted to explore the precise etiology of PE over the past decades. Some progress has been made toward the emerging consensus that PE is a heterogenic multisystem disorder and that a variety of theories such as endothelial dysfunction [5,6], maternal-fetal (paternal) immune maladaptation [7,8] and dysregulated inflammatory factors [9] have been suggestive of being the contributors to PE occurrence. To date, no definitive therapeutic interventions have been identified; and the only effective cure to treat PE is delivery of the placenta [3], which would lead to low birth-weight infant that brings about long-term adverse health effects such as cardiovascular disease [10]. Hence, it is of great significance to understand the underlying pathogenesis of the disease.

DNA methylation, the most extensively studied epigenetic modification, has been indicated to be involved in the development of human diseases [11–15]. Consequently, it is essential to understand the roles of DNA methylation in disease processes. Numerous studies have indicated high homocysteine in the plasma of pregnancies with PE [16–19], while multivitamin supplements containing folic acid and vitamin B12 are correlated with reduced risk of PE [17,19], which indicate the potential role of DNA methylation in the pathophysiology of PE. Furthermore, to acquire a deep insight into PE at the molecular level, the association of DNA methylation with PE has been intensively studied both in the gene-specific pattern [20–22] and in the genome-wide level [17,23]. In addition to the well-defined \( \text{SERPINAs} \) [22], \( \text{APC} \) [21] and \( \text{TIMPs} \) [23,24], a series of genes with differential methylation related to collagen metabolism, angiogenesis and blood vessel development have also been identified to be involved in PE with aberrant methylation patterns [17,25]. Given all that, DNA methylation appears to be a significant factor in the development of PE.
The causal relationship between promoter DNA methylation aberrations and gene expression differences has been well established. Promoter hypermethylation has been shown to associate with transcriptional repression and hence decreases expression and functional gene dosage; while demethylation in the promoter region will increase the transcription. Given the association of DNA methylation with PE mentioned above, we want to make an investigation of genes and functional networks with regard to epigenetics. So far, comparative gene expression profiling analyses of normal and pathological placentas have identified subsets of genes with altered expression [26]; however, few studies have been performed to explore the mechanisms that underlie the differential gene expression. Consequently, it is valuable to estimate the relative contribution of changes in DNA methylation levels to gene expression differences.

In the current study, we have performed a global gene expression profiling via oligonucleotide microarrays of placental tissue from pre eclamptic pregnancies and uncomplicated pregnancies to explore genes with differential expression. Among the differentially expressed genes in our study, we picked up LEP, the gene with biggest expression difference, and SH3PXD2A, the gene with the most significant p value, for further analysis to explore the relevance of DNA methylation in the development of PE as increasing studies suggested that aberrant DNA methylation was considered as a pathogenic factor in the onset of PE [20,27,28].

Materials and Methods

Ethics Statements

The study protocols were approved by the Ethics Review Committee of Fudan University and conducted according to the Declaration of Helsinki Principles. All participants in this manuscript have given written informed consent (as outlined in the PLoS consent form) to publish their details.

Patients and Samples

Placental tissues were obtained from pregnancies with PE (n = 23) and from uncomplicated pregnancies (n = 22) with singleton. All participants in the present study are Han Chinese in origin. Usually, diagnostics criteria used for PE patients were as follows: systolic pressure >140 mmHg, diastolic pressure >90 mmHg, and proteinuria >0.3 g in a 24 hours collection. The controls comprised the pregnancies undergoing caesarean section without suffering from other diseases. Clinical characteristics of all participants are shown in Table 1. For the microarray experiment, samples from 5 women with PE and 7 uncomplicated pregnancies were collected. For quantitative real-time PCR (qRT-PCR) validation, additional 7 pre eclamptic pregnancies and 6 normotensive pregnancies were included. For DNA methylation analysis, 16 clinical samples with PE and 16 control samples including samples used in microarray analysis were used to perform DNA methylation analysis. For linear correlation analysis, 12 placentas from normotensive pregnancies (5 placentas used in qRT-PCR and 7 placentas used in microarray analysis) were included. Materials of some placentas used in this study have been published in our previous study [29]. All clinical placentas from normal and pathological pregnancies were collected immediately after the caesarean section. Two ~1 cm³ fragments were dissected from the placenta, after removal of maternal blood by vigorous washing in phosphate buffered saline (PBS). The tissues were maintained in centrifuge tubes and RNA later (Ambion Inc., Austin, TX), and then frozen at −80°C.

Table 1. Clinical characteristics of the study population.

| Characteristic | PE (n = 23)* | Control (n = 22) | p-value† |
|---------------|-------------|-----------------|---------|
| Maternal age (years) | 30.95±0.64 | 28.5±3.73 | 0.387 |
| Gestational age (weeks) | 35.34±3.07 | 39.38±1.19 | 1.02×10⁻⁵ |
| Pregnancy BMI (kg/m²) | 30.72±3.49 | 31.45±3.76 | 0.616 |
| Systolic BP (mmHg) | 154.18±31.75 | 108.56±12.84 | 8.99×10⁻¹¹ |
| Diastolic BP (mmHg) | 106.27±15.07 | 68.69±8.93 | 8.99×10⁻¹¹ |
| Proteinuria (g/24 h) | 4.06±4.63 | 0 | 1.55×10⁻³ |
| Infant birthweight (g) | 2281.5±969.90 | 3406.2±293.83 | 2.94×10⁻⁴ |
| Placenta weight (g) | 402.6±143.29 | 692.14±74.38 | 2.35×10⁻⁵ |

All results are presented as mean ± SD.

*Diagnoses criteria used for PE patients were as follows: systolic pressure >140 mmHg, diastolic pressure >90 mmHg, and proteinuria >0.3 g in a 24 hours collection.

†Obtained using the Mann-Whitney U-test on SPSS version 16.0 (SPSS Inc., Chicago, IL, USA).

doi:10.1371/journal.pone.0059753.001

RNA Preparation

Total RNAs were extracted from placentas using the mirVana™ miRNA Isolation Kit (Ambion) according to manufacturer’s instruction, including a DNase I digestion step. The quality of RNA was determined by Nanodrop ND-1000 (NanoDrop Technologies, Wilmington, USA) and electrophoresis through denaturing gels.

Microarray Analysis

Microarray experiments were performed using the Roche Nimblegen Gene Expression 12×135 K Arrays. A total of 5 placentas from pregnancies with PE and 7 from normal subjects were included as discovery round samples in the hybridizations. Raw data were extracted as pair files by NimbleScan software (version 2.5), and Robust multi-array average (RMA) method was used to offer quantile normalization and background correction. The primary microarray data have been submitted to Gene Expression Omnibus with accession number GSE43942. To identify the differentially expressed genes, student’s t-test analysis was performed. The threshold we used to screen up or down-regulated genes is fold change >1.5 with a p value cut-off of <0.05. Gene Ontology (GO) and annotation analysis was conducted using DAVID Tools [30] for function analysis of the screened differentially expressed genes.

cDNA Preparation and Quantitative Real-time PCR

Reverse transcription was conducted with 1 μg RNA using M-MLV Reverse Transcriptase (Promega, Madison, WI, USA). qRT-PCR was performed to determine the mRNA expression of LEP and SH3PXD2A with FastStart Universal SYBR Green master (ROX) reagent (Roche Diagnostics, Basel, Switzerland) in 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA). An endogenous control gene, GAPDH was used as an internal control to normalize cDNA loadings among samples. Optimal qRT-PCR assay for LEP, SH3PXD2A and GAPDH (PCR primers were listed in Table S1) were designed on PrimerBank (http://pga.mgh.harvard.edu/primerbank). All qRT-PCR reactions were performed in replicates in a final volume of 10 μl containing primers, FastStart Universal SYBR Green master (ROX) reagent (Roche) and cDNA sample. Relative expression of selected genes in samples was quantified by normalized against GAPDH according to the 2⁻ΔΔCt method.
DNA Preparation, Bisulphite Conversion and Quantitative Methylation Analysis

Genomic DNA was isolated from placentas using the QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany). DNA was bisulphite-converted with the EZ DNA Methylation Kit (Zymo Research, Orange, CA, USA) according to the manufacturer's protocol. Quantitative methylation of LEP and SH3PXD2A was performed using the EpiTyper by MassArray (Sequenom, San Diego, CA, USA) based upon MassCLEAVE base-specific cleavage and MALDI-TOF mass spectrometry, as recommended by the manufacturer.

Cell Cultures

Human placental choriocarcinoma cell lines JEG-3 and human embryonic kidney cells (HEK293) were obtained from Cell Resource Center of Shanghai Institutes for Biological Sciences (Chinese Academy of Sciences, Shanghai, China). Both cell lines were repeatedly subcultured in Dulbecco's modified Eagle's medium (DMEM) (Gibco-BRL, Life Technology, Carlsbad, CA) supplemented with 10% fetal bovine serum and antibiotics (100 units/ml penicillin, 100 μg/ml streptomycin) in 5% CO2 humidified atmosphere at 37°C.

Constructions of Luciferase Vectors

DNA fragment encoding the human LEP promoter corresponding to the region from −279 to +94 was amplified through PCR. After digested with BglII/HindIII, the amplified fragment was purified and cloned into the promoter-less luciferase-reporter vector pGL3-Basic (Promega). A CEBPα was purified and cloned into the promoter-less luciferase-reporter PCR. After digested with HindIII, the amplified fragment was ligated with the CEBPα full-length cDNA and the pcDNA3.1/myc-His(-)/A expression vector (Life technologies). The primers used for DNA fragment amplifications above were summarized in Table S1.

Plasmids CpG Methylation

10 μg of LEP-pGL3 plasmids were in vitro methylated using 40 units of the CpG DNA methylase M.SssI (New England Biolabs) for 4 hours. The reaction was terminated by heating (65°C, 20 min). Methylated plasmids were purified by the DNA Clean & Concentratior Kit (Zymo Research). The efficiency of the methylation was examined by a BglII/HindIII digestion of the methylated LEP-pGL3 plasmids. The completeness of methylation was proven by the inhibition of BglII/HindIII digestion.

Transient Transfection of Cells and Luciferase Reporter Assay

24 hours prior to transfection, JEG-3 and HEK293 cells were seeded into 24-well plates containing media without antibiotics at a concentration sufficient to give 80% confluence. Transient transfection was carried out using Lipofectamine 2000 (Life Technologies), and pRL-CMV vector was used to correct for transfection efficiency. For each well, 0.8 μg of LEP-pGL3 or LEP (methyl)-pGL3 basic construct, 40 ng of pRL-CMV vector, and an optional 0.8 μg of CEBPα expression vector were diluted in 50 μl of Opti-MEM medium (Life Technologies); and 0.8 μl of Lipofectamine 2000 were diluted in 50 μl of Opti-MEM medium and incubated for 5 minutes at room temperature. After the combination of the diluted DNA and Lipofectamine 2000, the complexes were incubated for 20 min at room temperature to allow complex formation. The culture medium was replaced by 200 μl of Opti-MEM, and the plasmid-Lipo2000-OptiMEM complexes were added to the cells. Following 5 h of incubation at 37°C, 500 μl of medium containing 10% fetal bovine serum were added to replace previous medium. Twenty-four hours after transfection, the cells were washed once with PBS and lysed for subsequent measurement of both firefly and Renilla luciferase activities using Dual-Luciferase Reporter Assay System (Promega) with Luminoskan TL Plus (Thermo Labsystem) according to the manufacturer's procedures. The luciferase assay was repeated in triplicate independent experiments to reduce the variability and increase the accuracy.

Statistical Analysis

Descriptive statistics are presented as mean values ± SD. Statistical analysis is performed using the software SPSS version 16.0 software (SPSS Inc., Chicago, IL, USA). Differences of relative gene expression between pre eclamptic and normal placentas and the analysis of relative luciferase activity between groups were tested by student’s t-test. DNA methylation data is by excellence beta-distributed, and therefore the analysis comparing the DNA methylation in preeclamptic placentas with that of in control specimens were assessed by the non-parametric Mann-Whitney U-test. Gestational age was used as covariate to adjust the analysis of DNA methylation differences in PE placentas compared with controls, since these clinical characteristics significantly differed between the two groups. p value of less than 0.05 was considered as statistically significant.

Results

Overview of Gene Expression Microarray

To search for the differentially expressed genes between pathological placentas and controls, we conducted a NimbleGen gene expression microarray analysis. Applying Student t-test (p < 0.05) and a fold change criterion (>1.5 fold change in gene expression in pathological and control placentas) produced a set of 1312 genes with differential expression (Figure 1a). Among them, 367 probes (including 251 genes, 137 genes with up-regulation and 114 genes with down-regulation in preeclamptic placentas) had fold change differences greater than 2. Altogether, these genes included showed significant enrichment based on the gene ontology analysis (Figure 1b) such as regulation of cell growth, immune system and cell adhesion.

Consistent with our expectations, among the differentially expressed genes, there is a remarkable concordance of genes between our findings and other reported studies although we used different clinical samples and platforms, such as FLT1 [31], JAG1 [32] and ENG [33]. We have listed the overlapped genes of our microarray data in supplementary material Table S2.

Validation of the Differentially Expressed Genes: LEP and SH3PXD2A

To validate the results by NimbleGen gene expression microarray, qRT-PCR was carried out in additional 7 placentas from pregnancies with PE and in 6 placentas from healthy pregnancies. We chose the gene with the greatest expression difference (LEP, with the fold change = 18.832) and the gene with the most significant p value (SH3PXD2A, with p value = 1.41×10−7). The results here showed that the expression of LEP was significantly elevated in preeclamptic placentas, with 27.94-fold increase, compared with that in normal placentas (Figure 2a, p = 0.003). As for SH3PXD2A, it is consistent with our expectation that the expression increased in placentas from pregnancies with PE 2.53-fold compared with that in normal placentas (Figure 2b, p = 0.024).
DNA Methylation Analysis of LEP and SH3PXD2A

It is quite clear that DNA methylation has been a potentially important mechanism to regulate gene expression. In order to explore whether the different expressions of LEP and SH3PXD2A were influenced by the effect of DNA methylation, and to have a better understanding of the mechanism underlying the occurrence of PE, we made further investigation of DNA methylation of the relevant genes.

We analyzed the methylation patterns of LEP and SH3PXD2A in 32 placentas (16 pathological versus 16 normal placentas) using the high-throughput MALDI-TOF MS assay (Sequenom). The gene maps of LEP locus and SH3PXD2A locus were shown in Figure 3. The analyzed amplicons in the study comprised the CpG island (CGI) region in both genes. For LEP, three amplicons were designed to cover the whole CGI region, in which 62 CpG sites (40 units) per sample were amenable to be analyzed (Figure 3a). For SH3PXD2A which contains 6 CGIs, its upstream 4 CGIs (CGI71, CGI74, CGI8 and CGI34) were analyzed in the study and 88 CpG sites (54 units) per sample were able to be detected (Figure 3b).

In the LEP gene, most of the CpG sites in amplicon 1 and 2 are at a high degree of methylation (average methylation level >0.6
except unit 3), while the CpG sites in amplicon 3 around TSS show a low degree of methylation. Interestingly, we found that CpG dinucleotides situated around TSS [such as CpG sites determined to bind Sp1 (unit 28, average methylation = 0.193, 0.284 in preeclamptic vs normal placentas respectively, \( p = 1.57 \times 10^{-2} \)), LP1 (unit 29, average methylation = 0.163, 0.208 in preeclamptic vs normal placentas respectively, \( p = 0.023 \)] and CEBPα (unit 31, average methylation = 0.591, 0.689 in preeclamptic vs normal placentas respectively, \( p = 0.031 \)) and CpG sites in the position of TSS (unit 34, average methylation = 0.145, 0.198 in preeclamptic vs normal placentas respectively, \( p = 0.001 \)) were significantly hypomethylated in the placentas from pregnancies with PE (Figure 4a). In addition, we further tested the correlation between the DNA methylation and gene expression data, the result showed that LEP expression and differential LEP methylation was negatively correlated, but did not reach significant level (Figure S1).

![Figure 2](image_url)

Figure 2. Validation the mRNA expression of LEP and SH3PD2A in preeclamptic (n = 7) versus normal (n = 6) placentas. (A) Expression of LEP mRNA measured by qRT-PCR. The difference between preeclamptic placentas and normal controls is highly significant (\( p = 0.003 \)). **\( p < 0.01 \). Each bar represents the average relative expression compared with GAPDH. The average mRNA level of LEP and SH3PD2A in healthy controls was defined as 1. (B) Expression of SH3PD2A mRNA quantified by qRT-PCR. The expression of SH3PD2A is significantly elevated in placentas from pregnancies with PE (\( p = 0.024 \)). *\( p < 0.05 \). Each bar represents the average relative expression compared with GAPDH. The average mRNA level of SH3PD2A in healthy controls was defined as 1.

![Figure 3](image_url)

Figure 3. Schematic representation of LEP and SH3PD2A gene. (A) Maps of the TSS and the proximal promoter region of the human LEP gene. Positions and orientation of the MassARRAY primers are indicated by black arrows. (B) Maps of SH3PD2A locus presenting the CGIs region in the promoter region (CGI1) and in the gene body (CGI7, CGI18 and CGI34). Positions and orientation of the MassARRAY primers are indicated by black arrows.
In the SH3PXD2A gene, the CpG sites of the promoter region (amplicon 1) in both preeclamptic placentas and normal placentas are almost unmethylated with no statistical difference, which is in line with the hypothesis that the promoter CGI generally remains unmethylated. The methylation patterns in the gene body of SH3PXD2A (from unit 14 to 54) were shown in Figure 4b. All the CpG sites in CGI74 region (from unit 14 to 30) were also at a low methylation with no statistical difference between preeclamptic and control placentas. One CpG site (unit 34) in CGI 18 (from unit 31 to 39) were significantly hypomethylated in pathological placentas than that in normal placentas (the average methylation = 0.093, 0.203 in PE and control respectively, \( p = 0.002 \)). The remaining CpG sites in the CGI18 were also at a low methylation level. Interestingly, the CpG sites in the CGI34 region (Figure 4b, from unit 40 to 54) as a whole were at a high methylation level (the mean methylation = 0.725, 0.616 in PE and control respectively, \( p = 1.57 \times 10^{-4} \)). Most CpG sites are higher methylated in preeclamptic placentas than those in controls except unit 40 (including CpG 1 and CpG2), of which, unit 41, 42, 43, 44, 45, 47, 48, 49, 50, 51, 52, 53 and 54 were statistically significant \( (p = 0.003, 0.006, 0.007, 0.003, 1.90 \times 10^{-4}, 1.29 \times 10^{-4}, 0.004, 0.002, 0.007, 0.002, 1.29 \times 10^{-4}, 0.003 \) and \( 4.62 \times 10^{-5} \) respectively, Figure 4b). The correlation between DNA methylation level in CGI34 region and gene expression of SH3PXD2A in normal placentas was also performed. The result showed that gene body methylation and gene expression of SH3PXD2A was positively correlated without significance (Figure S2).

Clinical characteristic gestational age presented significant differences between groups, which might have influence on the statistical result. To adjust this, covariance analysis was performed. Our results indicated that the statistical significance of most CpG units showed no obvious difference after the correction except for unit 2 and unit 36 in LEP gene (Table S3).

Luciferase Analysis of DNA Methylation and Transcriptional Activity of LEP

To identify the effect of DNA methylation on the transcriptional activity of LEP promoter in placenta, the region (~279 to +84bp) placed 5’ adjacent to the reporter luciferase gene was in vitro methylated to further analyze its transcriptional activity in both JEG-3 and HEK293 cells. Methylation of CpG site within the CEBPz binding site participated in the down-regulation of LEP expression in adipose cells [34]. Hence, in our study, we cotransfected the cells with the target plasmids LEP-pGL3 or LEP (methyl)-pGL3 and an expression vector pcDNA-CEBPz. Consistent with our expectation, the relative light unit of CpG

---

**Figure 4. Quantitative DNA methylation of LEP and SH3PXD2A in all PE (n = 16) and control (n = 16) samples.** (A) The average methylation level of the CGI of LEP. Several CpG sites in the vicinity of TSS (unit 34) are all significantly hypomethylated in the preeclamptic placentas. Position with significantly differential methylation between PE and control groups is marked by asterisks. **\( p < 0.01 \), *\( p < 0.05 \). (B) The average methylation level of CGIs of SH3PXD2A. The TSS CGI comprised the CpG sites from unit 1 to 13; The CGI74 comprised the CpG sites from unit 14 to 30; The CGI18 comprised the CpG sites from unit 31 to 39; The CGI34 comprised the CpG sites from unit 40 to 54. Position with significantly differential methylation between PE and control groups is marked by asterisks. **\( p < 0.01 \), *\( p < 0.05 \). doi:10.1371/journal.pone.0059753.g004
DNA methylase M.SssI methylated construct showed a striking decrease compared with that in untreated construct in both cell lines (the relative light unit is 1.04, 171.16 in JEG-3 cells respectively, $p = 8.03 \times 10^{-6}$, Figure 5a; the relative light unit is 0.08, 4.64 in HEK293 cells respectively, $p = 6.21 \times 10^{-7}$, Figure 5b).

In addition, the relative light unit of transfection containing expression vector pcDNA-CEBP$\alpha$ is significantly stronger than that with LEP-pGL3 construct only (the relative light unit is 171.16 and 18.46 respectively, $p = 1.24 \times 10^{-5}$, Figure 5a; the relative light unit is 4.64, 0.39 in HEK293 cells respectively, $p = 1.34 \times 10^{-5}$, Figure 5b), which indicated that the transcription factor CEBP$\alpha$ is also necessary for the transcription of LEP in placental cells.

**Discussion**

In the present study, we applied gene expression microarray analysis to PE and control groups to search the candidate genes for following DNA methylation analysis. To control the maternal age and body mass index of pregnancies, the sample size used in the expression profile is small (5 placentas with PE and 7 controls), which might contribute to so many differentially expressed genes. However, among the differentially expressed genes, our current study and previous microarray analysis share a series of common genes listed in supplementary material Table S2. The homogeneity identified in our study suggested the effectiveness of our microarray analysis and the value to take further research. Based on the bioinformatics analysis, significantly enriched gene sets and pathways, including cell adhesion, immune response and pathways in cancer were identified through gene ontology (GO) database (Figure 1b) and KEGG database. They functionally suggested that the disease was heterogeneous and multi-factorial, that previous mentioned pathogenic theories such as the immune maladaptation between the mother and the fetus [7,8] and the impaired invasion of the extravillous trophoblast [35] are contributive to the occurrence of PE.

It is widely accepted that promoter DNA methylation plays a role in the regulation of gene expression in mammalian cells and is considered as an important contributor to disease states [36]. Among the genes with expression difference, LEP showed significant differences in DNA methylation in the CpG sites in the vicinity of TSS including the binding sites of transcription factors Sp1, LP1 and CEBP$\alpha$ in preeclamptic placentas compared with that in controls. Previous study in adipose cells [34] and our luciferase reporter assay in JEG-3 cells both pointed out that CEBP$\alpha$ expression was needed for stimulation of LEP promoter transcriptional activity and the methylation patterns of the CpG in the binding site of CEBP$\alpha$ participated in the regulation of LEP expression. As a result, we speculated that the demethylation in the corresponding CpG sites might influence the binding of the transcription factors, thereby led to the altered LEP expression in placentas from pregnancies with PE.

Leptin, the encoding protein of the LEP gene [37], which possesses pleiotropic effects with regulatory function in reproductive maturity and fertility such as regulation of ovarian function and implantation by promoting proliferation and survival of trophoblastic cells [38], has been repeatedly proven to be up-regulated not only in preeclamptic placentas [39–43], but also in the maternal plasma of pregnancies with PE [44]. In this regard, leptin must have played an important role in the development of PE, and it is necessary to reiterate the need for further research dedicated to elucidating its role in PE. Our study is so far the first report about the significant relationship between LEP proximal promoter methylation and PE. The small correlation coefficient between the DNA methylation and gene expression data is partially due to the small sample size used in the correlation study, which may also suggest that other mechanisms besides DNA methylation may involve in the regulation of gene expression.
Previous studies have demonstrated that the hormone hCG [45], estrogen [46], cAMP [47] and glucocorticoid response elements [48] are also confirmed to be responsible for the regulation of leptin expression. As a result, we have predicted that DNA methylation was a potential approach in the regulation of leptin expression. Consequently, current study measured the methylation level of 3 CGIs (CGI74, CGI18 and CGI34) of 10q24.33, is predicted with several transcriptive isoforms. These isoforms have reported the extravillous trophoblasts regulated extracellular matrix degradation through formation of atypical podosomes [55], which are of protrusive structures formed on the trophoblasts, and are also actin-rich and are able to degrade the extracellular matrix during the invasion. The degradation ability and dynamics of the structures have the characteristics of both podosome and invadopodia. The product encoding by SH3PXD2A in invadopodia or podosome formation that promotes cell metastasis [52–54]. Placenta is of pseudo-malignant nature, and trophoblast invasion is important for its formation. Patel et al. have reported the extravillous trophoblasts regulated extracellular matrix degradation through formation of atypical podosomes [55], which are of protrusive structures formed on the trophoblasts, and are also actin-rich and are able to degrade the extracellular matrix during the invasion. The degradation ability and dynamics of the structures have the characteristics of both podosome and invadopodia. The product encoding by SH3PXD2A may participate in the invasion of trophoblast cells in the formation of placenta, and PE is hallmarked by the deregulation of the trophoblast invasion, in this regard, we therefore speculated that the encoding protein by SH3PXD2A might take part in the development of PE.

It is worthy to note that the placentas used in our present study were all from pregnancies after delivery. Consequently, the differentially expressed genes in the microarray analysis were either responsible for the origin of PE or the consequence of the disease after the onset of PE. In summary, we adopted the gene expression microarray analysis between groups to search for the candidate genes for following DNA methylation analysis. The aberrant methylation of the interesting gene candidates LEP and SH3PXD2A might partially contribute to the deregulation of their expression. We are the first to report the relationship between LEP proximal promoter methylation and PE and our results firstly proposed an unexpected link between SH3PXD2A and the development of PE. The more detailed role of LEP, and especially SH3PXD2A need to be further studied in our following work.

Supporting Information

Figure S1 Correlation of differential LEP DNA methylation with gene expression. To increase the sample size of the correlation analysis and reduced the possible effect of the disease status, the linear correlation was performed based on normal placentas used in microarray and q-PCR analysis. (EPS)

Figure S2 Correlation of differential SH3PXD2A DNA methylation with gene expression. To increase the sample size of the correlation analysis and reduced the possible effect of the disease status, the linear correlation was performed based on normal placentas used in microarray and q-PCR analysis. (EPS)

Table S1 Sequences of PCR primers used in this study. (DOC)

Table S2 The overlapping genes in our microarray analysis with other published microarray papers. (DOC)

Table S3 Summary of adjusted and unadjusted statistical analyses for the Cpg units of LEP and SH3PXD2A genes by gestational age. (DOC)

Acknowledgments

We thank Dr. Xinyao Zhou (Fudan University) and Dr. Teng Wang (Fudan University) for excellent technical assistance.

Author Contributions

Conceived and designed the experiments: YX YC LH XZ. Performed the experiments: YX YC XL QL. Analyzed the data: YX JX JZ YL. Wrote the paper: YX YC LH XZ.

References

1. Redman CW, Sargent IL. (2005) Latest advances in understanding preeclampsia. Science 308: 1592–1594.
2. Shibai H, Decker G, Kupferminc M (2005) Pre-eclampsia. Lancet 365: 785–789.
3. Wang W, Feng L, Zhang H, Hachy S, Stuttskia S, et al. (2012) Preeclampsia up-regulates angiogenesis-associated microRNA (i.e., miR-17, -20a, and -20b) that target ephrin-B2 and EPHB4 in human placenta. J Clin Endocrinol Metab 97: E1051–1059.
4. Eland E, Nuezue G, Faulkner M (2012) Preeclampsia 2012. J Pregnancy 2012: 506378.
5. Maynard SE, Min JY, Merchaj J, Lim KH, Li J, et al. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649–658.
6. Roberts JM (1998) Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 16: 5–15.
7. Hennesy A, Pilmore HL, Simmons LA, Painter DM (1999) A deficiency of placental IL-10 in preeclampsia. J Immunol 163: 3491–3495.
8. Saito S, Shiozaki A, Nakashima A, Sakai M, Sasaki Y (2007) The role of the immune system in preeclampsia. Mol Aspects Med 28: 192–209.
9. Ramma W, Buhimschi IA, Zhao G, Dulay AT, Nayeri UA, et al. (2012) The elevation in circulating anti-angiogenic factors is independent of markers of neutrophil activation in preeclampsia. Angiogenesis 15: 333–340.
10. Barker DJ, Gluckman PD, Godfrey KM, Harding JE, Owens JA, et al. (1993) Fetal nutrition and cardiovascular disease in adult life. Lancet 341: 938-941.
11. Feinberg AP (2007) Phenotypic plasticity and the epigenetics of human disease. Nature 447: 433–440.
12. Gluckman PD, Hanson MA, Buklijas T, Low FM, Beadle AS (2009) Epigenetic mechanisms that underpin metabolic and cardiovascular diseases. Nat Rev Endocrinol 5: 401–408.
13. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128: 683–692.
14. Richardson B (2005) Primer: epigenetics of autoimmunity. Nat Clin Pract Rheumatol 3: 521–527.
15. Urdinguio RG, Sanchez-Mut JV, Esteller M (2009) Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol 8: 1056–1072.
16. Goren MA, Coskun A, Ertas IE, Aral M, Zencirci B, et al. (2009) Association of maternal serum CRP, IL-6, TNF-alpha, homocysteine, folic acid and vitamin
B12 levels with the severity of preeclampsia and fetal birth weight. Hypertens Pregnancy 28: 190–200.

17. Kulkarni A, Chavan-Gautam P, Mehandale S, Yadav H, Joshi S (2011) Global DNA methylation patterns in placenta and its association with maternal inflammation in pre-eclampsia. DNA Cell Biol 30: 79–84.

18. Makedos G, Papanicolaou A, Hitouli A, Kaloisannidis I, Makedos A, et al. (2007) Homocysteine, folic acid and B12 serum levels in pregnancy complicated with preeclampsia. Arch Gynecol Obstet 275: 121–124.

19. Sinha U, Gupta JP, Singh RK, Shukla M, Singh R, et al. (2000) A study of changes in homocysteine levels during normal pregnancy and pre-eclampsia. J Indian Med Assoc 106: 503–505.

20. Cheffi ST, Mondon F, Jammes H, Buffat C, Mignot TM, et al. (2007) Expressional and epigenetic alterations of placental serine protease inhibitors: SERPINA3 is a potential marker of preeclampsia. Hypertension 49: 76–83.

21. Chin SS, Tong YK, Chiu RW, Lau TK, Leung TN, et al. (2005) Detection of the placental epigenetic signature of the maspin gene in maternal plasma. Proc Natl Acad Sci U S A 102: 14753–14758.

22. Muller HM, Ivanison L, Schreckenadel H, Fieg H, Widenschwender A, et al. (2004) DNA methylation changes in sera of women in early pregnancy are similar to those in advanced breast cancer patients. Clin Chem 50: 1065–1068.

23. Yuen RK, Penaherrera MS, von Dadelszen P, McFadden DE, Robinson WP (2010) DNA methylation profiling of human placentas reveals promoter hypomethylation of multiple genes in early-onset preeclampsia. Eur J Hum Genet 18: 1006–1012.

24. Xiang Y, Zhang X, Li Q, Xu J, Zhou X, et al. (2012) Promoter hypomethylation of TIMP1 is associated with pre-eclampsia in a Chinese population. Mol Hum Reprod 18: 503–508.

25. Mosu AA, Cappello RE, Estrada-Gutierrez G, Shukla J, Romero R, et al. (2012) Preeclampsia is associated with alterations in DNA methylation of genes involved in placental development. Hum Genet 131: 1455–1463.

26. Louwen F, Muschio-Steinmetz C, Reinhard J, Reitter A, Yuan J (2012) A lesson for cancer research: placental microarray gene analysis in preeclampsia. Oncotarget 3: 759–773.

27. Knox KS, Baker JC (2007) Genome-wide expression profiling of human placentas reveals promoter hypomethylation of multiple genes in early-onset preeclampsia. Eur J Hum Genet 13: 251–256.

28. Nelisens EC, van Montfoort AP, Damoulion JC, Evers JL (2011) Epigenetics and the placenta. Hum Reprod Update 17: 397–417.

29. Zhao A, Cheng Y, Li X, Li Q, Wang L, et al. (2011) Promoter hypomethylation of histone H3K9 methylation in preeclampsia. J Matern Fetal Neonatal Med 21: 267–273.

30. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44–57.

31. Levine RJ, Qian C, Leshane ES, Yu KF, England LJ, et al. (2004) Two-stage DNA methylation changes in sera of women in early pregnancy are similar to those in advanced breast cancer patients. Clin Chem 50: 1065–1068.

32. Cervero A, Horcajadas JA, Domínguez F, Pellicer A, Simon C (2005) Leptin system in embryo development and implantation: a protein in search of a function. Reprod Biomed Online 10: 217–223.

33. Chelbi ST, Mondon F, Jammes H, Buffat C, Mignot TM, et al. (2007) Expressional and epigenetic alterations of placental serine protease inhibitors: SERPINA3 is a potential marker of preeclampsia. Hypertension 49: 76–83.

34. Jones PA (2012) Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 13: 49–52.

35. Kaufmann P, Black S, Huppertz B (2003) Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod 69: 1–7.

36. Gopalakrishnan S, Van Emburgh BO, Robertson KD (2008) DNA methylation in development and human disease. Mutat Res 647: 30–38.

37. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, et al. (1994) Positional cloning of the mouse ob gene and its human homologue. Nature 372: 425–432.

38. Makedos G, Papanicolaou A, Hitoglou A, Kalogiannidis I, Makedos A, et al. (2000) Effects of estrogen on leptin gene promoter activation in MCF-7 breast cancer and JEG-3 choriocarcinoma cells: selective regulation via estrogen receptors alpha and beta. Mol Cell Endocrinol 176: 67–75.

39. Kang JH, Song H, Yoon JA, Park DY, Kim SH, et al. (2011) Preeclampsia leads to dysregulation of various signaling pathways in placenta. J Hypertens 29: 928–936.

40. Sitras V, Paulsen RH, Gronaas H, Leirvik J, Hansen TA, et al. (2009) Differential placental gene expression in severe preeclampsia. Placenta 30: 424–433.

41. Varkonyi T, Nagy B, Tárca AL, Karaszi K, et al. (2011) Microarray profiling reveals that placental transcriptomes of early-onset HELLP syndrome and preeclampsia are similar. Placenta 32 Suppl: S21–S29.

42. Nakatokasa H, Maseyama H, Takamato N, Hiramatsu Y (2008) Circulating leptin and angiogenic factors in preeclampsia patients. Endocr J 55: 565–573.

43. Maymo JL, Perez Perez A, Sanchez-Margalet V, Duenas JL, Calvo JC, et al. (2009) Up-regulation of placental leptin by human chorionic gonadotropin. Endocrinology 150: 304–313.

44. O’Neil JS, Burrow ME, Green AE, McLachlan JA, Henson MC (2001) Effects of estrogen on leptin gene promoter activation in MCF-7 breast cancer and JEG-3 choriocarcinoma cells: selective regulation via estrogen receptors alpha and beta. Mol Cell Endocrinol 176: 67–75.

45. Maymo JL, Perez Perez A, Duenas JL, Calvo JC, Sanchez-Margalet V, et al. (2010) Regulation of placental leptin expression by cyclic adenosine 5’-monophosphate involves cross talk between protein kinase A and mitogen-activated protein kinase signaling pathways. Endocrinology 151: 3738–3751.

46. Maymo JL, Perez Perez A, Duenas JL, Calvo JC, Sanchez-Margalet V, et al. (2011) Review: Leptin expression in the placenta - regulation of a key hormone in trophoblast proliferation and survival. Placenta 32 Suppl 2: S146–153.

47. Jones PA (2012) Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 13: 494–492.

48. Abram CL, Seals DF, Pass I, Salinsky D, Maurer L, et al. (2003) The adaptor protein Tks family scaffold proteins. Sci Signal 2: pe56.

49. Selli SS, I ST, Kaye AH, Lock P (2012) Prognostic significance of Tsk5 expression in gliomas. J Clin Neurosci 19: 436–442.

50. Weaver AM (2009) Regulation of cancer invasion by reactive oxygen species and beyond. Nat Rev Genet 13: 484–492.

51. Abram CL, Seals DF, Pass I, Salinsky D, Maurer L, et al. (2003) The adaptor protein Tks family scaffold proteins. Sci Signal 2: pe56.

52. Patel A, Dash PK (2012) Formation of atypical podosomes in extravillous trophoblasts regulates extracellular matrix degradation. Eur J Cell Biol 91: 171–179.